BRPI0822462A2 - derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina. - Google Patents

derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina.

Info

Publication number
BRPI0822462A2
BRPI0822462A2 BRPI0822462A BRPI0822462A BRPI0822462A2 BR PI0822462 A2 BRPI0822462 A2 BR PI0822462A2 BR PI0822462 A BRPI0822462 A BR PI0822462A BR PI0822462 A BRPI0822462 A BR PI0822462A BR PI0822462 A2 BRPI0822462 A2 BR PI0822462A2
Authority
BR
Brazil
Prior art keywords
quinazoline
imidazo
inhibitors
quinoline derivatives
novel hand
Prior art date
Application number
BRPI0822462A
Other languages
English (en)
Inventor
Antonio Giordani
Francesco Makovec
Gianfranco Caselli
Lucio Claudio Rovati
Marco Lanza
Simona Zanzola
Stefano Mandelli
Original Assignee
Rottapharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Spa filed Critical Rottapharm Spa
Publication of BRPI0822462A2 publication Critical patent/BRPI0822462A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0822462A 2008-06-20 2008-06-20 derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina. BRPI0822462A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/057908 WO2009152868A1 (en) 2008-06-20 2008-06-20 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands

Publications (1)

Publication Number Publication Date
BRPI0822462A2 true BRPI0822462A2 (pt) 2015-10-13

Family

ID=40220723

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822462A BRPI0822462A2 (pt) 2008-06-20 2008-06-20 derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina.

Country Status (13)

Country Link
US (1) US8633208B2 (pt)
EP (1) EP2315588B1 (pt)
JP (1) JP2011524383A (pt)
KR (1) KR20110036583A (pt)
CN (1) CN102159208B (pt)
AU (1) AU2008357946B2 (pt)
BR (1) BRPI0822462A2 (pt)
CA (1) CA2728376C (pt)
ES (1) ES2401679T3 (pt)
MX (1) MX2010014394A (pt)
PT (1) PT2315588E (pt)
RU (1) RU2472508C2 (pt)
WO (1) WO2009152868A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1395963B1 (it) 2009-06-04 2012-11-02 Rottapharm Spa Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
TW201210597A (en) * 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
HUE041576T2 (hu) 2011-09-14 2019-05-28 Samumed Llc Indazol-3-karboxamid-származékok és alkalmazásuk Wnt/b-katenin szignalizáló útvonal inhibitorokként
NZ711598A (en) * 2013-03-14 2016-09-30 Dart Neuroscience Cayman Ltd Substituted naphthyridine and quinoline compounds as mao inhibitors
WO2015157005A1 (en) 2014-04-10 2015-10-15 E I Du Pont De Nemours And Company Substituted tolyl fungicide mixtures
CA2969856A1 (en) 2014-12-05 2016-06-09 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
EP3226867A4 (en) 2014-12-05 2018-05-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
JP6501251B2 (ja) * 2015-03-12 2019-04-17 国立大学法人 長崎大学 慢性疼痛の治療薬
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
CN105461626B (zh) * 2015-12-17 2018-05-08 浙江工业大学 芳环或稠杂环联3,4-二氢异喹啉类共轭结构化合物及其应用
MY199242A (en) 2016-06-01 2023-10-22 Samumed Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
BR112019008061A2 (pt) 2016-10-21 2019-09-17 Samumed Llc métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
EP4151627A1 (en) * 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
TWI846654B (zh) * 2018-11-06 2024-06-21 美商富曼西公司 經取代之甲苯基殺真菌劑
EP3735974A1 (en) * 2019-05-10 2020-11-11 Rottapharm Biotech S.r.l. Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2021104639A1 (en) 2019-11-29 2021-06-03 Rottapharm Biotech S.R.L. Use of 2-phenyl-6-(1h-imidazol-1-yl) quinazoline for the prevention of abuse and of side effects of at least one opioid
UY39189A (es) 2020-05-06 2021-12-31 Fmc Corp Fungicidas de tolilo sustituido y sus mezclas
KR20230124665A (ko) 2020-12-22 2023-08-25 노파르티스 아게 Cgas 관련 병태의 치료에 유용한 인돌 유도체

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
US6627647B1 (en) 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
AU2005205016B2 (en) * 2004-01-16 2010-07-15 F. Hoffmann-La Roche Ag 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system
ITTO20040125A1 (it) 2004-03-01 2004-06-01 Rotta Research Lab Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica
RU2304029C1 (ru) * 2005-11-07 2007-08-10 Открытое акционерное общество "Электростальский завод тяжелого машиностроения" Устройство для перемещения труб конечной длины
US7994181B2 (en) * 2006-08-03 2011-08-09 Rottapharm S.P.A. 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents

Also Published As

Publication number Publication date
RU2472508C2 (ru) 2013-01-20
US20110118289A1 (en) 2011-05-19
CN102159208A (zh) 2011-08-17
EP2315588A1 (en) 2011-05-04
AU2008357946B2 (en) 2013-06-20
RU2011101952A (ru) 2012-07-27
CA2728376C (en) 2015-05-12
JP2011524383A (ja) 2011-09-01
CN102159208B (zh) 2014-05-28
KR20110036583A (ko) 2011-04-07
AU2008357946A1 (en) 2009-12-23
MX2010014394A (es) 2011-05-19
CA2728376A1 (en) 2009-12-23
ES2401679T3 (es) 2013-04-23
US8633208B2 (en) 2014-01-21
WO2009152868A1 (en) 2009-12-23
PT2315588E (pt) 2013-03-25
EP2315588B1 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
PT2315588E (pt) Derivados de 6-1h-imidazo-quinazolina e quinolinas, novos inibidores de mao e ligandos de receptores de imidazolinas
LT3216803T (lt) Stabilūs ir tirpūs antikūnai, slopinantys vegf
AP2377A (en) Benzimidazole derivatives.
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
HUE055338T2 (hu) Indolamin-2,3-dioxigenáz-alapú immunterápia
NL2000537A1 (nl) Aminederivaten.
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
BRPI0910307A2 (pt) inibidores de hiv integrase
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
DK2344471T3 (da) 7-piperidinalkyl-3,4-dihydroquinolon-derivat
BRPI0820805A2 (pt) Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
BRPI0913188A2 (pt) moduladores de receptores 5-ht3, métodos de fabricação, e uso dos mesmos
ATE527260T1 (de) (dihydro)pyrroloä2,1-aüisoquinoline
DE502007005744D1 (de) Schallgedämpftes, gasführendes Bauteil
EP2023715A4 (en) Indoleamine-2,3-dioxygenase 2
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
EP2459573A4 (en) SUBSTITUTED 1,2-AZABORIN HETEROCYCLES
DK2148873T3 (da) 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
EP1992622A4 (en) 4- (3-benzoylaminophenyl) -6,7-dimethoxy-2-METHYLAMINOCHINAZOLINDERIVAT
BRPI0816679A2 (pt) Derivados de ftalazinona.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ROTTAPHARM BIOTECH S.R.L. (IT)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]